Articles On Imugene (ASX:IMU)

Ethics approval is confirmation Imugene has completed all the necessary pre-clinical safety and efficacy testing of PD1-Vaxx required to commence human clinical trials.

ShareCafeAustralia…One Hour In…ASX Down 47 Points – Breville Group (+4%); big broker upgrade. – Imugene (+6%); receives ethics approval to start the PD1-VAXX trial. – Marley Spoon (+6%); COVID has been a blessing for these guys. Seems there...

Summary Backed by an international leadership team with extensive commercialisation expertise in the sector, Imugene has developed a robust product portfolio, comprising four potential drugs. In 2020, Imugene intends to progress with Ph...

Summary Imugene?s preclinical research associated with mimotope vaccines targeting immune checkpoint inhibitors published in ?Frontiers in Immunology? journal. Research discovered that mimotope peptides when included in Imugene?s exclus...

The research has identified mimotope peptides that when incorporated into Imugene’s proprietary immunotherapeutic vaccine delivery platform generate antibodies.

HER-Vaxx is Imugene’s lead cancer immunotherapy candidate and is currently treating patients in a phase 2 study in gastric cancer.

Clinical stage Australian immuno-oncology company, Imugene Limited (ASX:IMU) is set to kickstart two clinical trials with B-cell immunotherapy - PD1-Vaxx and oncolytic virotherapy CF33 this year. Recently, Imugene presented presentations on...

The Independent Data Monitoring Committee (IDMC) members have no safety concerns regarding B-cell immunotherapy HER-Vaxx, and biotech player Imugene Limited (ASX:IMU) can continue with its Phase 2 trial without modification, confirmed IDMC...

The Independent Data Monitoring Committee’s role is to review study data and conduct a formal independent review of key data such as deaths, adverse reactions and laboratory results.

Australia’s clinical stage immuno-oncology company, Imugene Limited (ASX:IMU) will present the clinical plans for the initial Phase 1 trials of its oncolytic virus, Vaxinia (CF33-hNIS) and its PD-1 targeting cancer immunotherapy, PD1-Vaxx a...

The first-in-human phase 1 study of Vaxinia is in patients with advanced or metastatic melanoma, non-small cell lung, TNBC, bladder, head and neck, gastric, colorectal and renal cell cancers.

The company is developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours.

Australian-headquartered clinical stage immuno-oncology firm, Imugene Limited (ASX:IMU) is actively implementing risk mitigation and business continuity strategies amidst the global COVID-19 pandemic to continue with its planned activities....

The company is developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumors.

The company's lead product is HER-Vaxx, a therapeutic cancer vaccine for the treatment of gastric cancer and breast cancer.

The company is developing a range of treatments to activate the immune system of cancer patients.

The ASX is cracking down on biotech and health companies disclosures around possible coronavirus-linked products. Yesterday TBG Diagnostics (ASX:TDL) was suspended as the ASX looks into why it waited until Wednesday to reveal that a COVID19...

The company's lead product is HER-Vaxx, a therapeutic cancer vaccine for the treatment of gastric cancer and breast cancer.

The clinical stage immuno-oncology company is developing a range of new treatments seeking to activate the immune system of cancer patients.

The company's lead product is HER-Vaxx, a therapeutic cancer vaccine for the treatment of gastric cancer and breast cancer.

Australian-headquartered clinical stage immuno-oncology firm, Imugene Limited (ASX:IMU) has released another set of robust operational results for the half-year ended 31st December 2019. It was certainly a remarkable half-year for the biote...

The company's lead product is HER-Vaxx, a therapeutic cancer vaccine for the treatment of gastric cancer and breast cancer.

The company’s preclinical results present an effective treatment against Peritoneal carcinomatosis (PC) from pancreatic ductal adenocarcinoma (PDAC).

Imugene Announced Completion of GMP manufacturing and Toxicology Studies for PD1-Vaxx

Pre-clinical milestones have been met with GMP manufacturing, including final sterile fill and finish as well as processes completed by FDA inspected and qualified contract manufacturing organisations in the US.

Imugene (IMU) will trial its cancer immunotherapy treatment, PD10Vaxx, to patients in North America and Australia The treatment will be trialled on patients with non-small cell lung cancer, which is the most common type of lung cancer The...

Immuno-oncology company Imugene (ASX: IMU) is set to advance its PD1-Vaxx cancer immunotherapy by trialling the treatment in patients with non-small cell lung cancer. In an update to the market, the company said it plans to conduct a new st...

28 Jan 2020 - Immuno-therapy company Imugene (ASX:IMU) report that studies have shown their PD1-Vaxx cancer immunotherapy drug generates high levels of antibodies.

A Smash Hit by Imugene: Received Core US Patent for HER-Vaxx

The health sector was the most successful sector on the ASX in 2019. Various small caps made several breakthroughs including with nerve damage and macular degeneration. While cancer remains one fish that has yet to be fried there are small...

The patent provides method of composition and method of use protection to 2036.

14 Jan 2020 - Immuno-therapy company Imugene (ASX:IMU) has received the US patent for its HER-VAxx cancer treatment.

Imugene (IMU) has received a Notice of Grant from the United States Patent and Trademark Office to protect its HER-Vaxx cancer immunotherapy HER-Vaxx is a B-cell immunotherapy designed to treat tumours that over-express the HER-2/neu rece...

Imugene (ASX: IMU) has received a strong boost in protecting its intellectual property for the next 16 years after the US Patent and Trademark Office (USPTO) granted the immuno-oncology company with a patent for its HER-Vaxx cancer immunoth...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

You don’t need a PhD to run a biotech, but sometimes it helps, as these companies deal in one of the most complicated mysteries still to be solved today: the human body. Biotech CEOs and chairs tend to be the cross-over scientists. However,...

Australia-based clinical stage immuno-oncology player, Imugene Limited (ASX: IMU) has recently announced the appointment of Surgeon Scientist, Dr. Rebecca Auer to its newly formed OV (oncolytic virotherapy) Scientific Advisory Board. Dr. A...

Dr. Auer heads a research laboratory and is the principle investigator in related clinical trials.

New Zealand’s medicines regulator has recommended the country fall in line with Australia’s new codeine restrictions, and pharmaceutical companies are backing the decision. Yesterday, Medsafe recommended that all medications containing code...

Clinical-stage immuno-oncology player, Imugene Limited (ASX: IMU) recently notified that it has received firm commitments for a capital raising of up to $24.6 million that involves Placement of up to 683 million ordinary shares to sophistic...

The placement raised A$24.6 million and was well supported by existing investors and new sophisticated and institutional investors.

Paul Hopper is an Australian biotech entrepreneur who has been associated with a number of biotechnology companies.

Biopharmaceutical company Imugene is looking to raise up to $24.6 million in an equity raising targeted at institutions. 

The company’s securities are in a trading halt until Monday, December 2, or when an announcement is made to the market.

It can be difficult to swallow banker-sized executive salaries in an earnest but yet-to-achieve small cap. But there are as many moments when CEOs, managing directors, and executive chairmen and women earn their keep. We uncovered the top 1...

In a recent ASX update, Australian headquartered Imugene Limited (ASX: IMU) has notified that CF33 oncolytic virus CheckVacc and Vaxinia constructs have completed clinical grade GMP batches at the manufacturing facility, City of Hope Center...

CF33 is a highly potent, chimeric oncolytic poxvirus – a poxvirus refers to a large group of DNA viruses that cause smallpox and similar infectious diseases in vertebrates.

Clinical stage immuno-oncology company Imugene (ASX:IMU) has announced the appointment of Professor Prasad S. Adusumilli, MD FACS FCCP, to its newly formed oncolytic virotherapy Scientific Advisory Board.

The company’s vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments – this vision is backed by a growing body of clinical evidence and peer-reviewed research.

Imugene Limited (ASX: IMU) jumped 18 per cent on ASX following the completion of oncolytic virus CF33 and Vaxinia Pty Ltd acquisition on 18th November 2019. IMU closed the trading session at $0.053 with ~259 million shares in rotation on 18...